Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-12-29 (Crawled : 14:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.21%
H: 1.17%
C: 0.91%
treatment fda application license approval
Amylyx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application (NDA) for AMX0035 for the Treatment of ALS
Published: 2021-12-29 (Crawled : 13:30) - biospace.com/
AMLX | $1.97 -1.5% -1.52% 1M
|
| Email alert
Add to watchlist
amx0035 new drug treatment fda als application drug fda acceptance
NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies
Published: 2021-12-29 (Crawled : 12:30) - biospace.com/
NRXP 1 d | $3.025 -27.63% -38.18% 760K
|
Manufacturing
|
| O: 10.22%
H: 4.84%
C: 0.2%
covid-19 zyesami treatment aviptadil als risk covid media therapy breakthrough therapy designation
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
Published: 2021-12-29 (Crawled : 12:30) - biospace.com/
CANF | $2.02 3.06% -2.48% 10K
|
Health Technology
|
| O: 16.67%
H: 0.0%
C: -1.36%
treatment clearance solid tumors application patent liver cancer
Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Published: 2021-12-28 (Crawled : 22:00) - biospace.com/
TSOI | $0.0007 0.0% 13M
|
Manufacturing
|
| O: -1.44%
H: 139.02%
C: 138.54%
covid-19 treatment patent covid cancer
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
CELU | News F | $3.17 -4.23% -4.42% 42K
|
|
| O: 7.23%
H: 2.97%
C: -0.6%
cynk-001 fast track designation treatment fda fast track cel therapy designation aml
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2021-12-27 (Crawled : 13:30) - biospace.com/
MBRX | News | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -9.76%
treatment phase 1b trial phase 1 soft tissue phase 2b
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
Published: 2021-12-27 (Crawled : 12:00) - sutrobio.com
STRO M | $3.76 -1.05% -1.06% 770K
|
Health Technology
|
| O: 5.05%
H: 2.02%
C: -2.67%
stro-002 treatment biopharma expansion drug ovarian cancer cancer antibody
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
Published: 2021-12-21 (Crawled : 20:20) - jaguarhealth.gcs-web.com
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
covid-19 treatment approval covid molnupiravir antiviral merge
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.56%
H: 0.43%
C: -0.15%
cosentyx novartis treatment fda fda approval approval children
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Published: 2021-12-22 (Crawled : 20:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.51%
H: 2.25%
C: 0.51%
covid-19 treatment fda covid authorization antiviral merge emergency use authorization
Takeda Stumbles to be First EoE Treatment to Market Following FDA CRL
Published: 2021-12-22 (Crawled : 19:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
treatment fda
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2021-12-22 (Crawled : 15:00) - biospace.com/
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: -7.25%
H: 3.91%
C: -7.81%
treatment fda health approval diarrhea therapy crofelemer
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Published: 2021-12-22 (Crawled : 14:00) - biospace.com/
ALLR | $1.53 2.0% 1.96% 760K
|
n/a
|
| O: 4.76%
H: 35.91%
C: 14.77%
new drug treatment fda application renal drug therapeutics cel cell carcinoma
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
Published: 2021-12-22 (Crawled : 14:00) - biospace.com/
SGHT | News | $5.29 -1.67% -1.7% 160K
|
|
| O: 0.48%
H: 1.62%
C: -3.82%
tearcare dry eye treatment fda clearance eye eye disease disease
Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
Published: 2021-12-22 (Crawled : 13:30) - biospace.com/
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: -4.09%
H: 9.76%
C: 4.88%
mdna11 treatment cel phase 1 cancer
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Published: 2021-12-22 (Crawled : 13:30) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 2.86%
cejemly treatment ema als approval cel lung cancer china therapy cancer
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's
Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
Published: 2021-12-22 (Crawled : 12:30) - prnewswire.com
SNDX | $20.44 -1.45% -1.47% 1.2M
|
Health Technology
|
| O: -0.66%
H: 7.48%
C: 2.84%
sndx-5613 treatment myeloid leukemia europe 613 drug leukemia granted orphan drug grant designation acute myeloid leukemia
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.